Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: Are there differences?

International Journal of Neuropsychopharmacology

Volumn 8, Issue 2, 2005, Pages 153-156

  Meltzer, Herbert Y ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

BIPOLAR DISORDER; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIFESTYLE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; HUMANS; LONG-TERM CARE; RISPERIDONE; SCHIZOPHRENIA;

EID: 20044382698     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145705005183     Document Type: Review

References (15)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27, 596-601.
2. Atmaca M, Kuloglu M, Tezcan E, Ustundag B (2003). Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Journal of Clinical Psychiatry 64, 598-604.
3. Cordain L, Eades MR, Eades MD (2003). Hyperinsulinemic diseases of civilization: more than just Syndrome X. Comparative Biochemistry and Physiology. Part A, Molecular and Integrative Physiology 236, 95-112.
4. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP (2005). Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. International Journal of Nenropsychopharmacology 8, 175-182. DOI: 10.1017/S1461145705005067.
5. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of General Psychiatry 62, 19-28.
6. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F (2001). Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Archives of Internal Medicine 767, 361-366.
7. Koller EA, Weber J, Doraiswamy PM, Schneider BS (2004). A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. Journal of Clinical Psychiatry 65, 857-863.
8. Koro C, Fedder D, Gilbert J, Weiss S, Magder L, Revicki D, Buchanan R (2002a). An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenia patients. Archives of General Psychiatry 59, 1021-1026.
9. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW (2002b). Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. British Medical Journal 325, 243.
10. Melkersson K, Dahl ML (2004). Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64, 701-723.
11. Melkersson K, Hulting A-L, Brismar K (2000). Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia and related psychosis. Journal of Clinical Psychiatry 61, 742-749.
12. Meyer J (2002). A retrospective comparison of weight, lipid and glucose changes between risperidone and olanzapine treated inpatients: metabolic outcomes at one year. Journal of Clinical Psychiatry 63, 425-433.
13. Meyer JM, Koro CE (2004). The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research 70, 1-17.
14. Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A (2005). Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. International Journal of Neuropsychopharmacology 8, 183-194. DOI: 10.1017/S1461145705005110.
15. Sumiyoshi T, Roy A, Anil AE, Jayathilake K, Ertugrul A, Meltzer HY (2004). A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. Journal of Clinical Psychopharmacology 24, 345-348.